SCA
ABUS icon

SAC Capital Advisors’s Arbutus Biopharma ABUS Stock Holding History

SAC Capital Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-46,283
Closed -$995K – 10
2014
Q1 		$995K Buy
+46,283
New +$832K 0.01% 952

Other funds holding ABUS

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

SAC Capital Advisors's ABUS Position: Q2 2014 in Review

SAC Capital Advisors sold out of Arbutus Biopharma (ABUS) in Q2 2014, closing a stake of 46,283 shares — an estimated $995K sold.

SAC Capital Advisors first reported a position in ABUS in Q1 2014 and held it in 1 quarter. The position peaked at $995K in Q1 2014. 39 funds tracked by Wall St. Rank hold ABUS as of Q2 2014.

  • SAC Capital Advisors reported no remaining Arbutus Biopharma position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 46,283 Arbutus Biopharma shares in Q2 2014, an estimated $995K.
  • SAC Capital Advisors first reported a position in Arbutus Biopharma in Q1 2014 and held it in 1 quarter.
  • SAC Capital Advisors's Arbutus Biopharma position peaked at $995K in Q1 2014.
  • 39 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.